EpiCypher^® announces co-exclusive licensing of foundational CUT&RUN / CUT&Tag IP

Research Triangle Park, NC – Dec 15 2021 – – EpiCypher, Inc. announces the co-exclusive licensing of CUT&RUN / CUT&Tag technology from Fred Hutchinson Cancer Research Center. This agreement strengthens EpiCypher’s intellectual property portfolio that includes CUT&RUN / CUT&Tag workflows for both Research Use Only (RUO) and diagnostics applications. EpiCypher is now firmly established as the leading commercial developer of CUT&RUN / CUT&Tag reagents, kits, and assay services. Under this co-exclusive licensing partnership, EpiCypher will expand their CUTANA CUT&RUN and CUT&Tag product lines and explore new opportunities that increase access to these transformative epigenomic technologies.

CUT&RUN and CUT&Tag are rapidly replacing ChIP-seq as the preferred method to study histone post-translational modifications (PTMs) and chromatin-associated proteins. The new approaches require 10-fold fewer sequencing reads and can employ ultra-low cellular inputs, including single-cell analyses. Importantly, these assays are automation-compatible, thus enabling epigenomics analyses on scales that support drug development and clinical research.

CUT&RUN and CUT&Tag were created by the laboratory of Dr. Steven Henikoff, a Fred Hutch molecular biologist and Howard Hughes Medical Institute Investigator.

“EpiCypher’s CUTANA platform is changing the way researchers approach genomic mapping studies – especially for drug development,” said Dr. Michael-Christopher Keogh, Chief Scientific Officer at EpiCypher. “This foundational IP gives us the support to build next-generation assays that further improve assay sensitivity, throughput and cost.”“

This new co-exclusive licensing agreement strengthens EpiCypher’s existing patent portfolio, which includes fundamental IP covering DNA-barcoded nucleosomes and their use for antibody validation and quantitative sample normalization. EpiCypher is committed to leveraging this IP to revolutionize how researchers use epigenomics for drug development and clinical research.

“We look forward to exploring commercial partnership opportunities that expand global access to our technologies,” said Dr. Martis Cowles, Chief Business Officer at EpiCypher. “With our passion for innovation, EpiCypher is dedicated to delivering the full potential of CUT&RUN and CUT&Tag technology to accelerate drug development and improve human health.”“

About EpiCypher – Founded in 2012, EpiCypher^® was created in response to the growing demand for high-quality reagents and tools to study chromatin regulation and enable epigenetics-focused drug development. The Company brings transformative technologies to market and offers superior products and assay services to researchers worldwide. EpiCypher manufactures and sells fully defined “designer” nucleosomes (dNucs), which are integrated to the SNAP-ChIP^® product family for quantitative genomic mapping applications, and the dCypher^® assay platform to dissect the capability of epigenetic regulators in their physiological context. Currently, EpiCypher is at the cutting edge of chromatin mapping technologies with the recent launch of the CUTANA^® platform for ultra-sensitive ChIC, CUT&RUN, and CUT&Tag profiling assays. These provide major advantages compared to ChIP-seq, delivering high quality epigenomic data with an ease of adoption and price accessible to a broad range of researchers.

Media Contact: Leslie Lewis, EpiCypher, Inc. [email protected]